601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)

NCT04667910 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Central Retinal Vein Occlusion

Interventions

DRUG: 601 1.25mg
DRUG: Ranibizuman 0.5 mg

Sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.